Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

NCT07196306 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no participants enrolled

Conditions

COVID
COVID-19
Corona Virus Infection

Interventions

DRUG: Sarilumab 200 MG/1.14 ML Subcutaneous Solution
DRUG: Placebo

Sponsor

BayCare Health System